Molecular Pathway for Cancer Metastasis to Bone

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2003 Jul 30

PMID 12885781

Citations 56

Authors

Sarmishtha De

Juhua Chen

Natalya V Narizhneva

Warren Heston

Jennifer Brainard

E Helene Sage

Tatiana V Byzova

Affiliations

Soon will be listed here.

Abstract

The molecular mechanism leading to the cancer metastasis to bone is poorly understood but yet determines prognosis and therapy. Here, we define a new molecular pathway that may account for the extraordinarily high osteotropism of prostate cancer. By using SPARC (secreted protein, acidic and rich in cysteine)-deficient mice and recombinant SPARC, we demonstrated that SPARC selectively supports the migration of highly metastatic relative to less metastatic prostate cancer cell lines to bone. Increased migration to SPARC can be traced to the activation of integrins alphaVbeta3 and alphaVbeta5 on tumor cells. Such activation is induced by an autocrine vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-2 loop on the tumor cells, which also supports the growth and proliferation of prostate cancer cells. A consequence of SPARC recognition by alphaVbeta5 is enhanced VEGF production. Thus, prostate cancer cells expressing VEGF/VEGFR-2 will activate alphaVbeta3 and alphaVbeta5 on their surface and use these integrins to migrate toward SPARC in bone. Within the bone environment, SPARC engagement of these integrins will stimulate growth of the tumor and further production of VEGF to support neoangiogenesis, thereby favoring the development of the metastatic tumor. Supporting this model, activated integrins were found to colocalize with VEGFR-2 in tissue samples of metastatic prostate tumors from patients.

Citing Articles

Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy.

Sutherland M, Gordon A, Al-Shammari F, Throup A, La Corte A, Philippou H Cancers (Basel). 2023; 15(16).

PMID: 37627051 PMC: 10452181. DOI: 10.3390/cancers15164023.

A novel microRNA-182/Interleukin-8 regulatory axis controls osteolytic bone metastasis of lung cancer.

Zhao M, Zhang L, Sun Z, Qiao L, Yang T, Ren Y Cell Death Dis. 2023; 14(5):298.

PMID: 37127752 PMC: 10151336. DOI: 10.1038/s41419-023-05819-8.

SPARC Induces E-Cadherin Repression and Enhances Cell Migration through Integrin αvβ3 and the Transcription Factor ZEB1 in Prostate Cancer Cells.

Lopez-Moncada F, Torres M, Lavanderos B, Cerda O, Castellon E, Contreras H Int J Mol Sci. 2022; 23(11).

PMID: 35682554 PMC: 9180154. DOI: 10.3390/ijms23115874.

Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.

Bahmad H, Jalloul M, Azar J, Moubarak M, Samad T, Mukherji D Front Genet. 2021; 12:652747.

PMID: 33841508 PMC: 8033163. DOI: 10.3389/fgene.2021.652747.

Long Noncoding RNA and Transcription Factor HOXB13 Modulate the Expression of Bone Metastasis-Related Genes in Prostate Cancer.

Misawa A, Kondo Y, Takei H, Takizawa T Genes (Basel). 2021; 12(2).

PMID: 33514011 PMC: 7912412. DOI: 10.3390/genes12020182.

References

Lang S, Clarke N, George N, Testa N . Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. Clin Exp Metastasis. 1997; 15(3):218-27. DOI: 10.1023/a:1018465213641. View

Lane T, Sage E . The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J. 1994; 8(2):163-73. View

Sokoloff M, Chung L . Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer. Cancer Metastasis Rev. 1999; 17(4):307-15. DOI: 10.1023/a:1006170612253. View

Ferrer F, Miller L, Lindquist R, Kowalczyk P, Laudone V, Albertsen P . Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 1999; 54(3):567-72. DOI: 10.1016/s0090-4295(99)00156-9. View

Zheng D, Woodard A, Tallini G, Languino L . Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem. 2000; 275(32):24565-74. DOI: 10.1074/jbc.M002646200. View

Byzova T, Goldman C, Jankau J, Chen J, Cabrera G, Achen M . Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood. 2002; 99(12):4434-42. DOI: 10.1182/blood.v99.12.4434. View

Pecheur I, Peyruchaud O, Serre C, Guglielmi J, Voland C, Bourre F . Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J. 2002; 16(10):1266-8. DOI: 10.1096/fj.01-0911fje. View

Sage . 2 regulation of extracellular matrix and cell cycle in mice lacking the matricellular protein SPARC. You can believe your eyes. J Histochem Cytochem. 1999; 47(12):1643A-1643. View

Weidner N, Carroll P, Flax J, BLUMENFELD W, Folkman J . Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993; 143(2):401-9. PMC: 1887042. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Jacob K, Webber M, Benayahu D, Kleinman H . Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res. 1999; 59(17):4453-7. View

12.

Gerber H, Vu T, Ryan A, Kowalski J, Werb Z, Ferrara N . VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 1999; 5(6):623-8. DOI: 10.1038/9467. View

13.

Brekken R, Sage E . SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 2001; 19(8):816-27. DOI: 10.1016/s0945-053x(00)00133-5. View

14.

Thalmann G, Anezinis P, Chang S, Zhau H, Kim E, Hopwood V . Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994; 54(10):2577-81. View

15.

Byzova T, Goldman C, Pampori N, Thomas K, Bett A, Shattil S . A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell. 2000; 6(4):851-60. View

16.

Masood R, Cai J, Zheng T, Smith D, Hinton D, Gill P . Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 2001; 98(6):1904-13. DOI: 10.1182/blood.v98.6.1904. View

17.

Bazzoni G, Hemler M . Are changes in integrin affinity and conformation overemphasized?. Trends Biochem Sci. 1998; 23(1):30-4. DOI: 10.1016/s0968-0004(97)01141-9. View

18.

Gardiner E, DSouza S . A mitogenic action for fibrinogen mediated through intercellular adhesion molecule-1. J Biol Chem. 1997; 272(24):15474-80. DOI: 10.1074/jbc.272.24.15474. View

19.

Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Bicknell R . Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int. 2000; 85(3):276-80. DOI: 10.1046/j.1464-410x.2000.00432.x. View

20.

McHugh K, Hodivala-Dilke K, Zheng M, Namba N, Lam J, Novack D . Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000; 105(4):433-40. PMC: 289172. DOI: 10.1172/JCI8905. View